scanX
Home
Syngene International

Syngene International

713.75
-0.85
(-0.12%)
Market Cap
28,765.30 Cr
EPS
12.71
PE Ratio
60.28
Dividend Yield
0.17 %
Industry
Healthcare
52 Week High
960.60
52 Week low
607.65
PB Ratio
6.55
Debt to Equity
0.17
Add Ratio
Live Chart

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from9 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy55.56 %
55.56 %
Hold11.11 %
11.11 %
Sell33.33 %
33.33 %

Company News

View All News
Caret
negative
USFDA Issues Form 483 with 5 Observations for Syngene International's Bengaluru FacilitiesToday
The United States Food and Drug Administration (USFDA) has issued a Form 483 with five observations following an inspection of Syngene International's facilities in Bengaluru. Form 483 is issued when inspectors observe conditions that may constitute violations of the Food Drug and Cosmetic Act and related Acts. The company will need to respond to these observations and take corrective actions.

Peer Comparison Compare Peers on Screener

Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
Syngene International
 713.75 28,765.30 60.28 3,579.20 9.66 510 17.58 34.75
Indegene
 555.55 13,320.10 34.84 2,665.90 12.77 337 11.03 34.64
Suven Life Sciences
 117.60 2,583.10 - 32.80 49.09 -105 6.46 42.98
Vimta Labs
 946.75 2,145.00 35.25 322.30 0.22 41 112.87 48.85
Take Solutions
 11.23 158.70 - 67.20 -65.97 -120 2,371.43 42.26
Bilcare
 60.39 136.60 - 769.70 -22.39 -59 17.26 41.44
Jeevan Scientific Technology
 48.81 75.10 107.80 40.30 8.04 -1 120.00 56.21
Adeshwar Meditex
 17.50 24.20 30.45 80.00 -3.26 2 -80.00 36.86
Vanta Bioscience
 30.00 18.90 - 9.80 40.00 -9 -380.00 28.79
Growth Rate
Revenue Growth
9.66 %
Net Income Growth
9.82 %
Cash Flow Change
26.55 %
ROE
-6.70 %
ROCE
-3.05 %
EBITDA Margin (Avg.)
0.23 %

Quarterly Financial Results

Quarterly Financials
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
399
426
425
437
484
555
441
557
539
628
437
533
602
712
607
623
654
773
660
784
803
1,017
832
932
883
933
840
908
962
Expenses
262
280
297
292
327
374
300
325
366
403
297
364
408
443
430
464
438
508
472
552
555
680
596
663
626
600
620
646
660
EBITDA
138
146
128
145
158
181
142
231
174
225
140
170
193
269
177
160
216
265
188
232
248
337
236
268
257
333
220
261
302
Operating Profit %
33 %
32 %
27 %
30 %
30 %
30 %
29 %
30 %
30 %
34 %
30 %
30 %
30 %
33 %
28 %
24 %
32 %
33 %
27 %
28 %
29 %
32 %
26 %
27 %
27 %
35 %
22 %
27 %
30 %
Depreciation
35
34
37
40
43
44
47
53
57
62
66
69
70
70
75
76
79
80
86
90
95
96
102
105
108
111
107
111
109
Interest
5
7
8
8
8
8
7
8
10
9
7
7
7
7
8
1
9
6
9
12
14
10
11
13
11
13
12
13
12
Profit Before Tax
98
104
83
97
107
129
87
170
107
153
66
94
117
192
95
82
128
179
93
130
140
231
123
151
138
209
101
137
181
Tax
16
20
17
19
20
29
15
42
15
33
8
10
14
32
17
16
24
31
19
28
30
52
30
34
27
20
26
31
50
Net Profit
82
85
66
78
87
100
72
128
92
120
58
84
102
161
77
67
104
148
74
102
110
179
93
117
112
189
76
106
131
EPS in ₹
4.14
4.27
3.34
3.96
2.20
2.53
1.82
3.23
2.32
3.03
1.47
2.12
2.57
4.04
1.91
1.64
2.57
3.71
1.85
2.55
2.74
4.36
2.33
2.90
2.78
4.70
1.89
2.64
3.27
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2018
2019
2020
2021
2022
2023
2024
Total Assets
3,189
3,704
4,163
4,883
5,564
5,831
6,152
Fixed Assets
1,030
1,377
2,020
2,201
2,393
2,667
2,850
Current Assets
1,720
1,764
1,613
1,807
2,206
2,425
1,959
Capital Work in Progress
155
274
234
237
346
177
838
Investments
158
716
776
702
1,034
919
548
Other Assets
1,846
1,337
1,133
1,743
1,791
2,069
1,916
Total Liabilities
3,189
3,704
4,163
4,883
5,564
5,831
6,152
Current Liabilities
784
1,129
1,539
1,133
1,229
1,188
1,144
Non Current Liabilities
685
607
448
929
1,037
1,025
750
Total Equity
1,720
1,968
2,176
2,821
3,298
3,618
4,258
Reserve & Surplus
1,520
1,768
1,776
2,421
2,897
3,217
3,856
Share Capital
200
200
400
400
401
401
402
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
18
-88
28
130
-62
-172
-4
Investing Activities
-349
-646
-424
-629
-611
-653
-494
Operating Activities
446
630
677
701
581
824
1,042
Financing Activities
-79
-72
-226
58
-31
-343
-552
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
70.58 %
70.43 %
70.42 %
70.41 %
70.41 %
70.29 %
64.86 %
64.86 %
54.88 %
54.80 %
54.79 %
54.79 %
54.79 %
54.72 %
54.72 %
52.74 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.02 %
0.02 %
0.00 %
0.00 %
0.00 %
20.92 %
20.63 %
20.72 %
20.64 %
DIIs
4.02 %
3.81 %
4.03 %
3.64 %
3.26 %
2.79 %
4.96 %
7.04 %
10.73 %
11.20 %
9.94 %
13.08 %
15.80 %
16.80 %
17.48 %
19.53 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
8.05 %
8.29 %
8.46 %
9.20 %
9.22 %
9.02 %
8.81 %
8.57 %
8.39 %
8.10 %
7.53 %
7.24 %
6.45 %
6.08 %
5.45 %
5.59 %
Others
17.35 %
17.46 %
17.09 %
16.76 %
17.11 %
17.90 %
21.36 %
19.52 %
25.98 %
25.90 %
27.73 %
24.89 %
2.03 %
1.77 %
1.62 %
1.50 %
No of Share Holders
1,15,632
1,26,395
1,36,749
1,37,892
1,33,610
1,28,278
1,34,334
1,27,964
1,24,014
1,25,455
1,25,992
1,21,880
1,15,850
1,20,018
1,07,338
1,28,806

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 1 0.5 0.00 0.00 1 1.25 1.25 0.00
Dividend Yield (%) 0.00 0.00 0.34 0.21 0.00 0.00 0.17 0.18 0.17 0.00

Corporate Action

Announcements

Update On Pre-Approval And Cgmp Inspection By United States Food & Drug Administration (USFDA).
5 hours ago
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.
6 days ago
Intimation Of Cancellation Of Meetings With Analysts/Institutional Investors
Feb 10, 2025, 20:38
Announcement under Regulation 30 (LODR)-Change in Management
Feb 10, 2025, 20:19
Announcement under Regulation 30 (LODR)-Change in Management
Feb 10, 2025, 20:17
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Feb 10, 2025, 19:50
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Feb 05, 2025, 18:34
Grant Of Performance Share Units Under Syngene Long-Term Incentive Performance Share Plan 2023 (Plan)
Feb 01, 2025, 21:13
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.
Jan 29, 2025, 12:54
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Jan 28, 2025, 17:51
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.
Jan 27, 2025, 12:30
Announcement under Regulation 30 (LODR)-Newspaper Publication
Jan 24, 2025, 18:48
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Jan 23, 2025, 19:38
Intimation Of Amendment Of Code Of Practices And Procedures For Fair Disclosure Of Unpublished Price Sensitive Information (UPSI) Of The Company.
Jan 23, 2025, 18:56
Intimation Of Change In Key Managerial Personnel (KMP) To Determine Materiality Of An Event Or Information
Jan 23, 2025, 18:50
Integrated Filing (Financial)
Jan 23, 2025, 18:15
Announcement under Regulation 30 (LODR)-Investor Presentation
Jan 23, 2025, 18:08
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Jan 23, 2025, 18:05
Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024.
Jan 23, 2025, 15:06
Board Meeting Outcome for Outcome Of The Board Meeting - January 23 2025
Jan 23, 2025, 15:00
Revised Intimation Of Conference Call For Analysts And Investors
Jan 17, 2025, 23:25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Jan 15, 2025, 19:00
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.
Jan 14, 2025, 16:05
Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ending December 31 2024.
Jan 13, 2025, 12:09
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Jan 10, 2025, 18:26
Amendment To The Syngene Employee Welfare Trust Deed.
Jan 01, 2025, 16:10
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Dec 27, 2024, 15:00
Closure of Trading Window
Dec 27, 2024, 14:44

Technical Indicators

RSI(14)
Neutral
34.99
ATR(14)
Less Volatile
24.25
STOCH(9,6)
Neutral
36.69
STOCH RSI(14)
Overbought
90.86
MACD(12,26)
Bullish
2.46
ADX(14)
Strong Trend
43.65
UO(9)
Bearish
53.04
ROC(12)
Downtrend And Accelerating
-4.22
WillR(14)
Neutral
-53.66
Bearish
5
Neutral
2
Bullish
2
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Price & Volume Screeners
Fundamental Screeners
Technical Screeners
Candlestick Screeners
Intraday Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Corporate Office: A-302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai – 400066, Maharashtra, India. Land Line: 022-43116666.